Prostate Cancer

The paradigm of "more energy is better" is not limited to space travel, and in fact is center stage in a growing debate in the field of radiation oncology.

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Robert Dreicer, from the Cleveland Clinic, Discusses Sequencing MDV3100 and Abiraterone

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on Helping Patients Make Informed Medical Decisions

Dr. David Crawford, from University of Colorado Health Sciences Center, Discusses Transperineal 3D Mapping Biopsy

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the Challenges of PSA Screening

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Radium-223 in Early Prostate Cancer

Dr. Robert Dreicer, from the Taussig Cancer Institute at the Cleveland Clinic, Discusses Using Abiraterone Acetate

An interview with Nicholas J. Vogelzang, MD, during the ASCO 2012 Genitourinary Cancers Symposium, about treatment of prostate cancer and unmet needs.

EBRT led to more long-term toxicity and higher treatment-related costs compared with radical prostatectomy or brachyherapy.

Dr. Supriya Mohile from the University of Rochester Medical Center Discusses Prostate Cancer in Elderly Patients

The investigational agent MDV3100 extended survival in men with late-stage castration-resistant prostate cancer in the phase III AFFIRM trial.

IMRT was superior to CRT in reducing recurrence and significant side effects in men with localized prostate cancer, according to a comparative effectiveness study based on the SEER-Medicare database.

PSA testing was shown to significantly reduce mortality among men, but the test had no effect on all-cause mortality.

Once injectable agents were proven to lower testosterone levels, they became the preferred treatment among patients and their treatment teams.

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

A meta-analysis shows no apparent association between androgen deprivation therapy and cardiovascular events and death in men with prostate cancer.

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

Annual prostate cancer screening does not decrease mortality from prostate cancer more than opportunistic screening.

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223